Luye Pharma GroupFRA:LUP +3.03%47 Median PS Value is €0.38 as of Jul. 03, 2026, which is 100% below its 10-year median of 0.67. GuruFocus rates FRA:LUP with a GF Score™ of 47/100 and a GF Value™ of €0.32 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 545 Drug Manufacturers companies, Luye Pharma Group ranks better than 79.45% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Luye Pharma Group's Median PS Value or its related term are showing as below:
FRA:LUP'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.45 Med: 0.67 Max: 0.72
Current: 0.54
During the past 13 years, the highest Price to Median PS Value of Luye Pharma Group was 0.72. The lowest was 0.45. And the median was 0.67.
FRA:LUP's Price-to-Median-PS-Value is ranked better than 79.45% of 545
companies
in the Drug Manufacturers industry
Industry Median: 0.86
vs FRA:LUP: 0.54
Luye Pharma Group (FRA:LUP) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Luye Pharma Group's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.204
/
0.38
=
0.54
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group Median PS Value Related Terms
Luye Pharma Group Median PS Value Historical Data
* Premium members only.
The historical data trend for Luye Pharma Group's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luye Pharma Group Price-to-Median-PS-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Luye Pharma Group's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.9388.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.196.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group (FRA:LUP) has a Median PS Value of €0.38 as of Jul. 03, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Luye Pharma Group and its competitors. This is 43% below median its historical median of 0.67. Over the past decade, Luye Pharma Group's Median PS Value has ranged from 0.45 to 0.72. According to the industry distribution chart, Luye Pharma Group ranks #112 out of 545 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Luye Pharma Group's Median PS Value too high?
Luye Pharma Group's current Median PS Value of €0.38 is 43% below median its 10-year median of 0.67. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.72. Based on the distribution chart, Luye Pharma Group ranks #112 out of 545 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Luye Pharma Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Luye Pharma Group's Median PS Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Luye Pharma Group ranks #112 out of 545 companies for Median PS Value. This places Luye Pharma Group in the top 21% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.86. Historically, Luye Pharma Group's own Median PS Value has ranged from 0.45 to 0.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Drug Manufacturers company?
The median Median PS Value among Drug Manufacturers companies is 0.86, based on 545 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Luye Pharma Group and its competitors. For the Drug Manufacturers industry, the median Median PS Value is 0.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Luye Pharma Group's current Median PS Value is €0.38, which is 43% below median its own 10-year median of 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Luye Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Luye Pharma Group (FRA:LUP) is currently considered Possible Value Trap. The stock's GF Value™ is €0.32, compared to a current price of €0.20 — trading 36.3% below its estimated fair value. The current Median PS Value is €0.38, which is 43% below median its 10-year median of 0.67. Luye Pharma Group's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Luye Pharma Group (FRA:LUP), the current Median PS Value is €0.38 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Luye Pharma Group (FRA:LUP) Overvalued in 2026?
Based on GuruFocus' analysis, Luye Pharma Group stock appears to be undervalued.
The current stock price of €0.20 is trading 36.3% below its estimated GF Value™ of €0.32.
GuruFocus considers Luye Pharma Group to be Possible Value Trap.
Key valuation signals for FRA:LUP:
Median PS Value: €0.38 (43% below median its 10-year median of 0.67)
GF Value™: €0.32 vs. price of €0.20 (36.3% below fair value)
No single metric tells the full story. See the FRA:LUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on development, production, marketing and sale of pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company develops drugs for world-wide use in Asia, Europe, and the United States. The Group organizes its business segments by type of products. Oncology drugs, which derives maximum revenue; Cardiovascular system drugs; Alimentary tract and metabolism drugs; Central nervous system drugs; and others. Geographically, the group derives maximum revenue from Chinese Mainland, while it also has its presence in Asia (other than the Chinese mainland), European Union, and Other countries.
47GF Score
Get the complete analysis for FRA:LUP
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LUP has been successfully added to your 
